WallStreetZenWallStreetZen

NASDAQ: ARCT
Arcturus Therapeutics Holdings Inc Stock

$31.06-1.30 (-4.02%)
Updated Jun 12, 2024
ARCT Price
$31.06
Fair Value Price
-$25.71
Market Cap
$836.50M
52 Week Low
$17.52
52 Week High
$45.00
P/E
-7.71x
P/B
3.17x
P/S
7.29x
PEG
N/A
Dividend Yield
N/A
Revenue
$124.53M
Earnings
-$107.30M
Gross Margin
100%
Operating Margin
-95.81%
Profit Margin
-86.2%
Debt to Equity
0.59
Operating Cash Flow
$12M
Beta
1.22
Next Earnings
Aug 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ARCT Overview

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ARCT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ARCT ($31.06) is overvalued by 220.83% relative to our estimate of its Fair Value price of -$25.71 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ARCT ($31.06) is not significantly undervalued (220.83%) relative to our estimate of its Fair Value price of -$25.71 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ARCT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ARCT due diligence checks available for Premium users.

Be the first to know about important ARCT news, forecast changes, insider trades & much more!

ARCT News

Valuation

ARCT fair value

Fair Value of ARCT stock based on Discounted Cash Flow (DCF)
Price
$31.06
Fair Value
-$25.71
Undervalued by
220.83%
ARCT ($31.06) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ARCT ($31.06) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ARCT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ARCT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-7.71x
Industry
-9.14x
Market
30.03x

ARCT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.17x
Industry
6.31x
ARCT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ARCT's financial health

Profit margin

Revenue
$38.0M
Net Income
-$26.8M
Profit Margin
-70.5%
ARCT's Earnings (EBIT) of -$119.31M... subscribe to Premium to read more.
Interest Coverage Financials
ARCT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$418.8M
Liabilities
$154.9M
Debt to equity
0.59
ARCT's short-term assets ($375.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARCT's short-term assets ($375.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARCT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ARCT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$5.6M
Investing
-$240.0k
Financing
$2.2M
ARCT's operating cash flow ($12.22M)... subscribe to Premium to read more.
Debt Coverage Financials

ARCT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ARCT$836.50M-4.02%-7.71x3.17x
TNGX$813.10M+9.97%-6.86x3.07x
NRIX$810.99M+2.17%-6.20x4.81x
PRTC$810.12M0.00%-12.42x1.75x
COGT$864.35M+2.49%-3.65x2.05x

Arcturus Therapeutics Holdings Stock FAQ

What is Arcturus Therapeutics Holdings's quote symbol?

(NASDAQ: ARCT) Arcturus Therapeutics Holdings trades on the NASDAQ under the ticker symbol ARCT. Arcturus Therapeutics Holdings stock quotes can also be displayed as NASDAQ: ARCT.

If you're new to stock investing, here's how to buy Arcturus Therapeutics Holdings stock.

What is the 52 week high and low for Arcturus Therapeutics Holdings (NASDAQ: ARCT)?

(NASDAQ: ARCT) Arcturus Therapeutics Holdings's 52-week high was $45.00, and its 52-week low was $17.52. It is currently -30.98% from its 52-week high and 77.28% from its 52-week low.

How much is Arcturus Therapeutics Holdings stock worth today?

(NASDAQ: ARCT) Arcturus Therapeutics Holdings currently has 26,931,826 outstanding shares. With Arcturus Therapeutics Holdings stock trading at $31.06 per share, the total value of Arcturus Therapeutics Holdings stock (market capitalization) is $836.50M.

Arcturus Therapeutics Holdings stock was originally listed at a price of $52.85 in May 22, 2013. If you had invested in Arcturus Therapeutics Holdings stock at $52.85, your return over the last 11 years would have been -41.23%, for an annualized return of -4.72% (not including any dividends or dividend reinvestments).

How much is Arcturus Therapeutics Holdings's stock price per share?

(NASDAQ: ARCT) Arcturus Therapeutics Holdings stock price per share is $31.06 today (as of Jun 12, 2024).

What is Arcturus Therapeutics Holdings's Market Cap?

(NASDAQ: ARCT) Arcturus Therapeutics Holdings's market cap is $836.50M, as of Jun 13, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Arcturus Therapeutics Holdings's market cap is calculated by multiplying ARCT's current stock price of $31.06 by ARCT's total outstanding shares of 26,931,826.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.